Physician profile
Daniel R Reed
NPI 1053386466
$510.96
in general payments reported to CMS, 2019-2025
11 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.53 · 2021: $79.57 · 2022: $69.08 · 2024: $153 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $139.64 | 2019-2025 | Spaceoar Vue System - 10ml |
| Siemens Medical Solutions USA, INC. | $133.40 | 2021-2024 | Varian Ethos Treatment Planning |
| Abbvie INC. | $77.01 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.66 | 2025 | |
| Pfizer INC. | $23.79 | 2024 | |
| Palette Life Sciences, INC. | $23.67 | 2022 | |
| Janssen Biotech, INC. | $22.25 | 2025 | Erleada |
| Advanced Oxygen Therapy INC. | $15.66 | 2025 | Topical Oxygen Chamber For Extremities |
| Convatec INC. | $15.09 | 2019 | |
| Pharmaand Gmbh | $6.48 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.